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1. INTRODUCTION {#clc23159-sec-0005}
===============

Growth differentiation factor‐15 (GDF‐15), first named as macrophage inhibitory cytokine‐1 (MIC‐1),was a stress‐response member of transforming growth factor‐β cytokine superfamily. It was found that GDF‐15 messenger RNA (mRNA) expressing increased during macrophage activation.[1](#clc23159-bib-0001){ref-type="ref"} Normally GDF‐15 is weakly expressed in most tissues under physiological conditions but its expression level may sharply upregulate in response to ischemia‐reperfusion injury, reactive oxygen species, and mechanical stretch, possibly mediated through pro‐inflammatory cytokine and oxidative stress dependent signaling pathways.[2](#clc23159-bib-0002){ref-type="ref"}, [3](#clc23159-bib-0003){ref-type="ref"} Moreover, it had suggested that elevated GDF‐15 was a cardioprotective cytokine when exposed to cardiovascular injury in an animal model.[3](#clc23159-bib-0003){ref-type="ref"} In humans, increased GDF‐15 had been observed in atherosclerotic plaque macrophages.[4](#clc23159-bib-0004){ref-type="ref"}

To date, cardiovascular diseases (CVDs), a leading cause of mortality worldwide, have brought heavy burden to social healthcare and individuals. Thus, intensive investigation has been focused on controlling the risk factors aimed at lowering CVD risks. Plenty of clinical research has been conducted to explore the relationship between GDF‐15 levels and CVDs. These experiments conclusively demonstrate that GDF‐15 levels link to the adverse cardiovascular events across a spectrum of CVD conditions including heart failure (HF), chest pain, acute coronary syndromes (ACS), stable ischemic heart disease, stroke, and atrial fibrillation.[5](#clc23159-bib-0005){ref-type="ref"}, [6](#clc23159-bib-0006){ref-type="ref"}, [7](#clc23159-bib-0007){ref-type="ref"}, [8](#clc23159-bib-0008){ref-type="ref"} The potential ability of GDF‐15 may attribute to the earlier diagnosis, risk stratification and prognosis assessment. However, no systematic review and meta‐analysis have analyzed the available data pertaining to the association between GDF‐15 levels and CVDs or all‐cause mortality. Hence, we perform a meta‐analysis for the purpose of qualitatively and quantitatively assessing the relationship between GDF‐15 levels and CVDs or all‐cause mortality.

2. MATERIALS AND METHODS {#clc23159-sec-0006}
========================

2.1. Literature Search {#clc23159-sec-0007}
----------------------

Following the Preferred Reporting Items for Systematic Reviews and Meta‐Analysis guideline, we searched PubMed and ISI Web of Science databases from January 1, 1950 to December 31, 2017 for the terms "growth differentiation factor‐15" or "macrophage inhibitory cytokine 1"or "placental transforming growth factor beta" or "non‐steroidal anti‐inflammatory drug‐activated gene‐1" or "prostate‐derived factor" and "cardiovascular disease" or "coronary heart disease" or "ischemic heart disease" or "myocardial infarction" or "heart failure" or "stroke" or "all‐cause mortality"or "acute coronary syndrome" or "troponin." The retrieval process was independently completed by two authors (S. Xie and L. Liu). In addition, we also retrieved the reference list of the selected studies and recent reviews for obtaining further information. The literature search was restricted to human studies and published in English language.

2.2. Inclusion and exclusion criteria {#clc23159-sec-0008}
-------------------------------------

Studies were eligible for inclusion if they met the following criteria: (a) prospective cohort study, (b) follow‐up duration of at least 3 months, (c) reported at least one of the interesting outcomes: major cardiovascular endpoints (cardiovascular death, myocardial infarction, stroke, and HF) or all‐cause mortality, (d) provided relative risk (RR) or hazard ratio (HR) with 95% confidence interval (CI) for GDF‐15 levels comparing the highest levels to the lowest or definite increases for risk factor as a continuous variable (data after logarithmic transformation). [s]{.smallcaps}tudies were excluded if the study design was review articles, case‐controlled studies ,retrospective cohort studies, commentaries, editorials, or case report; studies concerning ecological ,animal, or cell culture, genetic variation in GDF‐15 relevant genes were not selected; we also excluded the study population based on non‐adult.

### 2.2.1. Data extraction {#clc23159-sec-0009}

Two investigators (S. Xie and L. Liu) performed the relevant data extraction with discrepancies reconciled through deliberation with a third investigator (L. Lu).The information was extracted as follows: authors, publication year, sample size, characteristics of the baseline population, mean age of the participants, study location, mean levels of GDF‐15, detective method, follow‐up, study endpoints, total number of related events, RR or HR with 95% CI, covariates adjusted for in multivariable analyses. The data from different sub‐cohort of the same study was extracted separately.

2.3. Assessment of study quality {#clc23159-sec-0010}
--------------------------------

According to the Newcastle‐Ottawa quality assessment scale (for cohort study), the assessment of including study quality was performed following three aspects: participants selection, comparability of groups, and ascertainment of outcome. A study can be awarded a maximum of one score for each numbered item within the selection. A maximum of two scores can be given for comparability and selection. Higher scores of studies represented better quality.

2.4. Statistical analyses {#clc23159-sec-0011}
-------------------------

Various studies reported the results in different patterns and presented the effect sizes for comparison between groups or for a given unit of increase in GDF‐15 levels. To display the results more concise and understandable, we assessed the association between GDF‐15 categorical level and the risk of CVD mortality or all‐cause mortality or complex adverse outcome (composite of death or cardiovascular events), by comparing the highest category of GDF‐15 with the lowest. We also analyzed GDF‐15 level as a continuous variable to evaluate the risk of CVD mortality or all‐cause mortality or complex adverse outcome based on per log‐unit increase of GDF‐15. Pooled HR with 95% CI was presented as an effect size for estimating the association between GDF‐15 levels and the risk of CVD mortality or all‐cause mortality or complex adverse outcome. In the process of handling the data, the SD of log‐GDF‐15 was estimated from the Framingham Heart Study, Framingham, MA.[9](#clc23159-bib-0009){ref-type="ref"} A random‐effect model was applied to pool the data across studies.[10](#clc23159-bib-0010){ref-type="ref"} For assessing the extent of divergence, the heterogeneity of trials was examined by Q‐statistic and quantified by the I^2^ statistic. It was considered that a relatively larger extent of I^2^ represented greater heterogeneity. We undertook meta‐regression analysis to explore the possible reason resulted in heterogeneity. According to the different characteristics of including studies, subgroup analyses were performed, respectively, stratified by the sample size (≤1000 or \>1000), duration of follow‐up (≤5 years or\>5 years), assay method (enzyme‐linked immunosorbent assay, radioimmunoassay, or others), whether to adjust the variable, and baseline population (general population, coronary heart disease, others). Sensitivity analysis was performed to appraise an excessive estimate of a single study by way of eliminating each study individually. An estimation of potential publication bias was performed by both Egger\'s linear regression test. All statistical analysis was performed with software package Stata version 12.0 (STATA Corp LP, Texas). *P* \< 0.05 was identified with a statistical significance.

3. RESULTS {#clc23159-sec-0012}
==========

3.1. Identification of studies {#clc23159-sec-0013}
------------------------------

The procedures of literature retrieval and selection were present in Figure [1](#clc23159-fig-0001){ref-type="fig"}. We initially retrieved 886 relevant publications from the PubMed and ISI Web of Science electronic databases. The majority of these were excluded after screening the titles or abstracts, because of editorials/reviews/case reports/cross‐sectional design or not related. Twenty studies did not provide interesting outcomes, 18 articles were excluded because the data provided were insufficient or unavailable, one study was excluded because of duplicate report on the same study population, and one study follow‐up duration was less than 3 months. Finally, 29 studies were selected in our meta‐analysis.

![Flow chart of study selection process for meta‐analysis](CLC-42-513-g001){#clc23159-fig-0001}

3.2. Study characteristics {#clc23159-sec-0014}
--------------------------

Table [1](#clc23159-tbl-0001){ref-type="table"} displayed the baseline characteristics of participants across the 29 studies. The eligible trials involved a total of 53 706 participants. Six[9](#clc23159-bib-0009){ref-type="ref"}, [20](#clc23159-bib-0020){ref-type="ref"}, [21](#clc23159-bib-0021){ref-type="ref"}, [22](#clc23159-bib-0022){ref-type="ref"}, [23](#clc23159-bib-0023){ref-type="ref"}, [28](#clc23159-bib-0028){ref-type="ref"} studies enrolled community‐based populations, 17[6](#clc23159-bib-0006){ref-type="ref"}, [11](#clc23159-bib-0011){ref-type="ref"}, [12](#clc23159-bib-0012){ref-type="ref"}, [13](#clc23159-bib-0013){ref-type="ref"}, [14](#clc23159-bib-0014){ref-type="ref"}, [15](#clc23159-bib-0015){ref-type="ref"}, [16](#clc23159-bib-0016){ref-type="ref"}, [17](#clc23159-bib-0017){ref-type="ref"}, [18](#clc23159-bib-0018){ref-type="ref"}, [19](#clc23159-bib-0019){ref-type="ref"}, [27](#clc23159-bib-0027){ref-type="ref"}, [29](#clc23159-bib-0029){ref-type="ref"}, [31](#clc23159-bib-0031){ref-type="ref"}, [32](#clc23159-bib-0032){ref-type="ref"}, [34](#clc23159-bib-0034){ref-type="ref"}, [36](#clc23159-bib-0036){ref-type="ref"}, [37](#clc23159-bib-0037){ref-type="ref"} studies were restricted to patients with coronary artery disease (CAD), five[5](#clc23159-bib-0005){ref-type="ref"}, [7](#clc23159-bib-0007){ref-type="ref"}, [24](#clc23159-bib-0024){ref-type="ref"}, [25](#clc23159-bib-0025){ref-type="ref"}, [30](#clc23159-bib-0030){ref-type="ref"} studies were on HF, and the remaining three were respectively pertaining to diabetes mellitus (DM),[26](#clc23159-bib-0026){ref-type="ref"} atrial fibrillation (AF)[33](#clc23159-bib-0033){ref-type="ref"} and intensive care unit patients.[35](#clc23159-bib-0035){ref-type="ref"} The mean age of the subjects ranged from 42 to 79 years. The median follow‐up duration ranged from 0.25 to 11.3 years. Table [2](#clc23159-tbl-0002){ref-type="table"} showed the estimates of association between GDF‐15 levels and risk of adverse outcomes included in the meta‐analysis. Nineteen[5](#clc23159-bib-0005){ref-type="ref"}, [7](#clc23159-bib-0007){ref-type="ref"}, [11](#clc23159-bib-0011){ref-type="ref"}, [12](#clc23159-bib-0012){ref-type="ref"}, [13](#clc23159-bib-0013){ref-type="ref"}, [14](#clc23159-bib-0014){ref-type="ref"}, [15](#clc23159-bib-0015){ref-type="ref"}, [16](#clc23159-bib-0016){ref-type="ref"}, [18](#clc23159-bib-0018){ref-type="ref"}, [21](#clc23159-bib-0021){ref-type="ref"}, [23](#clc23159-bib-0023){ref-type="ref"}, [24](#clc23159-bib-0024){ref-type="ref"}, [25](#clc23159-bib-0025){ref-type="ref"}, [27](#clc23159-bib-0027){ref-type="ref"}, [29](#clc23159-bib-0029){ref-type="ref"}, [30](#clc23159-bib-0030){ref-type="ref"}, [34](#clc23159-bib-0034){ref-type="ref"}, [36](#clc23159-bib-0036){ref-type="ref"}, [37](#clc23159-bib-0037){ref-type="ref"}studies individually regarded the GDF‐15 level as a continuous variable to evaluate the risk of CVDs, 7[6](#clc23159-bib-0006){ref-type="ref"}, [17](#clc23159-bib-0017){ref-type="ref"}, [20](#clc23159-bib-0020){ref-type="ref"}, [26](#clc23159-bib-0026){ref-type="ref"}, [28](#clc23159-bib-0028){ref-type="ref"}, [32](#clc23159-bib-0032){ref-type="ref"}, [33](#clc23159-bib-0033){ref-type="ref"} studies only regarded the GDF‐15 level as a categorical variable and 5[9](#clc23159-bib-0009){ref-type="ref"}, [19](#clc23159-bib-0019){ref-type="ref"}, [22](#clc23159-bib-0022){ref-type="ref"}, [31](#clc23159-bib-0031){ref-type="ref"}, [35](#clc23159-bib-0035){ref-type="ref"} studies utilized both two ways. Among the 31 trials, seven reported CVD mortality as outcomes, 13 reported complex adverse outcome, and 20 reported all‐cause mortality as outcomes. And the estimate of association between GDF‐15 levels and risk of adverse outcomes of included studies was yielded in the Table [2](#clc23159-tbl-0002){ref-type="table"}.

###### 

Baseline characteristics of the identified studies

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Source                                                       No. of Patients                    Baseline population                          Nation            Age (y)   Follow‐up (y)   Events number   Assay Method   Quality score
  ------------------------------------------------------------ ---------------------------------- -------------------------------------------- ----------------- --------- --------------- --------------- -------------- ---------------
  Wollert et al,[11](#clc23159-bib-0011){ref-type="ref"}       2079                               NSTE‐ACS(GUSTO‐IV trial)                     Germany           66        1               143             RIA            7

  Eitel et al,[12](#clc23159-bib-0012){ref-type="ref"}         238                                STEMI (LIPSIA‐N‐ACC)                         Germany           67        0.5             36              ELISA          6

  Kempf et al,[13](#clc23159-bib-0013){ref-type="ref"}         741                                AMI                                          Germany           67        1               59              RIA            6

  Eggers et al,[14](#clc23159-bib-0014){ref-type="ref"}        950                                NSTE‐ACS (FRISC II trial)                    Sweden            67.1      5               220             RIA            7

  Kempf et al,[15](#clc23159-bib-0015){ref-type="ref"}         2229                               CHD (AtheroGene Study)                       Germany           61.5      3.6             188             RIA            7

  Khan et al,[16](#clc23159-bib-0016){ref-type="ref"}          1142                               AMI                                          UK                67        1.38            303             ELISA          6

  Damman et al,[17](#clc23159-bib-0017){ref-type="ref"}        1151                               NSTE‐ACS(ICTUS)                              The Netherlands   62        5               236             RIA            7

  Lin et al,[18](#clc23159-bib-0018){ref-type="ref"}           216                                STEMI                                        Taiwan            59.8      2.33            18              ELISA          7

  Schopfer et al,[6](#clc23159-bib-0006){ref-type="ref"}       984                                Ischemic heart disease                       USA               66.7      8.9             478             ELISA          7

  Bonaca et al,[19](#clc23159-bib-0019){ref-type="ref"}        3501                               ACS (PROVE IT‐TIMI 22 trial)                 USA               58.1      2               317             RIA            7

  Izumiya et al, 2014[7](#clc23159-bib-0007){ref-type="ref"}   149                                Heart Failure                                Japan             69.9      1.96            16              ELISA          7

  Wang et al,[9](#clc23159-bib-0009){ref-type="ref"}           3428                               General population (FHS)                     USA               59        11.3            824             ECLIA          9

  Daniels et al,[20](#clc23159-bib-0020){ref-type="ref"}       1740                               General population (RBS)                     USA               71        11              521             ELISA          8

  Eggers et al,[21](#clc23159-bib-0021){ref-type="ref"}        1004                               General population (PIVUS)                   Sweden            70        8               111             RIA            8

  Rohatgi et al,[22](#clc23159-bib-0022){ref-type="ref"}       3291                               General population (DHS)                     USA               48.7      7.3             120             ELISA          9

  Wallentin et al,[23](#clc23159-bib-0023){ref-type="ref"}     940                                General population\                          Sweden            71        9.8             265             ECLIA          9
                                                                                                  (ULSAM)                                                                                                                 

  Lok et al,[24](#clc23159-bib-0024){ref-type="ref"}           209                                DEAL‐HF                                      The Netherlands   71        8.7             151             ECLIA          8

  Foley et al, 2009[25](#clc23159-bib-0025){ref-type="ref"}    158                                Patients with heart failure undergoing CRT   UK                68        2.6             52              ELISA          7

  Lajer et al,[26](#clc23159-bib-0026){ref-type="ref"}         891                                Type 1 diabetic patients With Nephropathy    Denmark           42.1      8.1             229             ECLIA          9

  Schnabel et al,[27](#clc23159-bib-0027){ref-type="ref"}      1781                               CAD (AtheroGene Study)                       Germany           63        3.6             137             ELISA          7

  Wiklund et al,[28](#clc23159-bib-0028){ref-type="ref"}       876                                Male cohort (general population)             Sweden            68        5.3             102             ELISA          7

  324                                                          Twin cohort (general population)   78.6                                         9.1               214                                                      

  Kempf et al, [5](#clc23159-bib-0005){ref-type="ref"}         455                                Chronic Heart Failure                        Germany           64        3.33            117             RIA            6

  Widera et al,[29](#clc23159-bib-0029){ref-type="ref"}        754                                NSTE‐ACS                                     Germany           70        0.5             66              RIA            6

  Richter et al,[30](#clc23159-bib-0030){ref-type="ref"}       349                                advanced systolic HF                         Austria           75        4.9             195             ELISA          6

  Velders et al,[31](#clc23159-bib-0031){ref-type="ref"}       5385                               STEMI treated with PPCI (PLATO trial)        Multicenter       59        1               199             ECLIA          5

  Dallmeier et al,[32](#clc23159-bib-0032){ref-type="ref"}     1029                               Stable CHD                                   Germany           59        10              162             ECLIA          6

  Wallentin et al,[33](#clc23159-bib-0033){ref-type="ref"}     14 798                             Atrial fibrillation                          Multicenter       70        1.9             1061            ECLIA          6

  Eggers et al,[34](#clc23159-bib-0034){ref-type="ref"}        453                                Acute chest pain                             Germany           66        5.8             92              RIA            7

  Dieplinger et al,[35](#clc23159-bib-0035){ref-type="ref"}    530                                ICU patients                                 Austria           68        0.25            118             ECLIA          4

  Tzikas et al,[36](#clc23159-bib-0036){ref-type="ref"}\       1804\                              Acute chest pain\                            Germany\          62\       0.5\            63\             Other\         6\
  Skau et al,[37](#clc23159-bib-0037){ref-type="ref"}          847                                AMI                                          Sweden            70        6.9             207             Other          7
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AMI, acute myocardial infarction; CAD, coronary artery disease; CHD, coronary heart disease; CRT, cardiac resynchronization therapy; DEAL‐HF, Deventer‐Alkmaar Heart Failure study; DHS, Dallas Heart Study; ECLIA, electrochemiluminescence assay; ELISA: enzyme‐linked immunosorbent assay; FHS, Framingham Heart Study; FRISC II: Fragming and Fast Revascularization during Instability in Coronary artery disease II; GUSTO‐IV trial: Global Utilization of Strategies to Open Occluded Arteries (GUSTO)‐IV trial; ICTUS: Invasive vs Conservative Treatment in Unstable coronary Syndromes; ICU, intensive care unit; LIPSIA‐N‐ACC: Leipzig Immediate Percutaneous coronary Intervention Acute myocardial infarction N‐Acetyl Cysteine; NSTE‐ACS: Non‐ST‐elevation myocardial infarction; PIVUS: Prospective Investigation of the Vasculature in Uppsala Seniors; RBS: Rancho Bernardo Study; RIA: radioimmunoassay; STEMI: ST‐elevation myocardial infarction; ULSAM: Uppsala Longitudinal Study of Adult Men; al‐HeFT, Valsartan Heart Failure Trial.

###### 

Estimates of association between GDF‐15 levels and risk of adverse outcomes included in the meta‐analysis

  Study                                                        Endpoints                                                  Comparison                                                 HR (95% CI)                                               Adjustments
  ------------------------------------------------------------ ---------------------------------------------------------- ---------------------------------------------------------- --------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Wollert et al,[11](#clc23159-bib-0011){ref-type="ref"}       All‐cause mortality                                        Per SD                                                     1.49 (1.2‐1.85)                                           Age, gender, delay time, current smoking, history of HTN, hypercholesterolemia, diabetes, previous angina pectoris, MI, revascularization, history of HF, and ST‐segment depression≥0.5 mm
  Eitel et al,[12](#clc23159-bib-0012){ref-type="ref"}         Mortality                                                  Per SD                                                     2.51 (1.59‐3.96)                                          Unadjusted
  MACE[a](#clc23159-note-0003){ref-type="fn"}                  Per SD                                                     2.51 (1.58‐3.96)                                                                                                     
  Kempf et al,[13](#clc23159-bib-0013){ref-type="ref"}         Mortality                                                  Per SD                                                     1.55 (1.14‐2.11)                                          Age, gender, delay time, current smoking, hypertension, diabetes mellitus, history of myocardial infarction, and trial (ASSENT‐2 vs ASSENT‐plus)
  Eggers et al,[14](#clc23159-bib-0014){ref-type="ref"}        Death                                                      Per log‐unit                                               3.4 (2.0‐5.8)                                             Age, gender, diabetes, heart failure, and previous MI
  Death/recurrent MI                                           1.9 (1.3‐2.8)                                                                                                                                                                   
  Kempf et al,[15](#clc23159-bib-0015){ref-type="ref"}         Coronary heart disease mortality                           Per SD                                                     2.4 (1.7‐3.4)[b](#clc23159-note-0004){ref-type="fn"}      Age, gender, HTN, diabetes, smoking, LDL/HDL‐ratio, number of diseased vessels, history of MI, and all indicated biomarkers
  1.6 (1.2‐2.1)[c](#clc23159-note-0005){ref-type="fn"}                                                                                                                                                                                         
  Khan et al [16](#clc23159-bib-0016){ref-type="ref"}          Death                                                      Per log‐unit                                               1.83 (1.06‐3.15)                                          Age, gender, previous history of AMI, HF, HTN, DM, smoking history, territory of infarction, STEMI or NSTEMI, Killip class, eGFR, troponin I, therapy with ACE inhibitors, angiotensin receptor blockers and beta‐blockers, NT‐proBNP, and GDF‐15
  Death or heart failure                                       1.77 (1.03‐3.05)                                                                                                                                                                
  Damman et al,[17](#clc23159-bib-0017){ref-type="ref"}        Death                                                      Highest level vs lowest t (\>1800 ng/L vs \<1200 ng/L)     6.12 (3.45‐10.9)                                          Unadjusted
  Death or spontaneous MI                                      3.14 (2.18‐4.52)                                                                                                                                                                
  Lin et al,[18](#clc23159-bib-0018){ref-type="ref"}           Death or HF                                                Per log‐unit                                               13.39 (2.8‐63.89)                                         Age, DM
  Schopfer et al,[6](#clc23159-bib-0006){ref-type="ref"}       All‐cause mortality                                        Highest tertile vs lowest                                  2.73 (1.80‐4.15)                                          Age, gender, race, smoking, HTN, DM, eGFR, stroke, LDL, exercise capacity, inducible ischemia, NT‐proBNP, CRP, leptin
  MI, stroke, or CV death                                      1.59 (0.99‐2.55)                                                                                                                                                                
  Bonaca et al, 2011[19](#clc23159-bib-0019){ref-type="ref"}   Death                                                      Highest level vs lowest *t* (\>1800 ng/L vs \<1200 ng/L)   1.91 (0.84‐4.32)                                          Age, sex, BMI, DM, HTN, current smoking, prior MI, qualifying event, and creatinine clearance, BNP, hsCRP
  Per log‐unit                                                 2.95(1.65‐5.26)                                                                                                                                                                 
  Death/MI                                                     Highest level vs lowest *t* (\>1800 ng/L vs \<1200 ng/L)   1.52 (1.05‐2.19)                                                                                                     
  Per log‐unit                                                 2.14(1.58‐2.91)                                                                                                                                                                 
  Izumiya et al,[7](#clc23159-bib-0007){ref-type="ref"}        All‐cause mortality/cardiac events\*                       Per log‐unit                                               4.74 (1.26‐17.88)                                         Age, atrial fibrillation, BNP
  Wang et al,[9](#clc23159-bib-0009){ref-type="ref"}           Death                                                      Highest quartile vs lowest                                 3.7 (2.34‐5.86)                                           Age, sex, BMI, SBP, HTN therapy, diabetes, cigarette smoking, total cholesterol, HDL cholesterol
  Per SD                                                       1.66 (1.51‐1.81)                                                                                                                                                                
  Major cardiovascular event                                   Highest quartile vs lowest                                 1.56 (1.03‐2.36)                                                                                                     
  Per SD                                                       1.26 (1.12‐1.41)                                                                                                                                                                
  Daniels et al,[20](#clc23159-bib-0020){ref-type="ref"}       Coronary revascularization, MI or CVD death                Highest quartile vs lowest                                 1.59 (0.96‐2.64)                                          Age, sex, DM, HTN, current smoking, SBP, total cholesterol, HDL cholesterol, creatinine clearance, BMI
  CVD death                                                    2.46 (1.17‐5.18)                                                                                                                                                                
  All--cause death                                             2.56 (1.66‐3.94)                                                                                                                                                                
  Eggers et al,[21](#clc23159-bib-0021){ref-type="ref"}        All‐cause mortality                                        Per log‐unit                                               4.0 (2.7‐6.0)                                             Sex, HTN, diabetes, HDL cholesterol, LDL cholesterol, current smoking, BMI, previous CVD, ln (CRP), and ln (eGFR)
  CVD mortality                                                2.3 (1.1‐5.0)                                                                                                                                                                   
  Rohatgi et al,[22](#clc23159-bib-0022){ref-type="ref"}       All‐cause mortality                                        Highest level vs lowest (\>1800 ng/L vs \<1200 ng/L)       3.5 (2.1‐5.9)                                             Age, sex, race, HTN, diabetes, current smoking, hypercholesterolemia, low HDL‐cholesterol, BMI, CKD stage, LV mass/body surface area, and history of CVD
  Per log‐unit                                                 2.4 (1.7--3.4)                                                                                                                                                                  
  CV death                                                     Highest level vs lowest(\>1800 ng/L vs \<1200 ng/L)        2.5 (1.1‐5.8)                                                                                                        
  Per log‐unit                                                 1.8 (1.1‐3.2)                                                                                                                                                                   
  Wallentin et al,[23](#clc23159-bib-0023){ref-type="ref"}     All‐cause mortality                                        Per SD                                                     1.35 (1.18‐1.53)                                          Age, current smoking, BMI, systolic blood pressure, antihypertensive treatment, total cholesterol, HDL cholesterol, lipid‐lowering treatment, type 2 diabetes, previous cancer, troponin T, NT‐proBNP, Cystatin C, CRP
  CVD mortality                                                1.22 (1.01‐1.48)                                                                                                                                                                
  Lok et al,[24](#clc23159-bib-0024){ref-type="ref"}           All‐cause mortality                                        Per SD                                                     1.41 (1.11‐1.78)[d](#clc23159-note-0006){ref-type="fn"}   Age, gender, eGFR HF etiology NT‐proBNP GDF‐15, hs‐TnT, Gal‐3 and/or hs‐CRP
  Foley et al,[25](#clc23159-bib-0025){ref-type="ref"}         All‐cause mortality                                        Per log‐unit                                               5.59 (2.69‐11.4)                                          Unadjusted
  CVD mortality                                                5.31 (2.31‐11.9)                                                                                                                                                                
  CVD mortality or heart failure hospitalizations              3.77 (1.75‐7.90)                                                                                                                                                                
  Lajer et al,[26](#clc23159-bib-0026){ref-type="ref"}         All‐cause mortality                                        Highest quartile vs lowest                                 4.86 (1.37‐17.30)                                         Sex age, smoking, A1C, systolic BP, cholesterol GFR, NT‐proBNP, antihypertensive treatment, and a history of cardiovascular events at baseline
  CVD mortality                                                5.59 (1.23‐25.43)                                                                                                                                                               
  Schnabel et al,[27](#clc23159-bib-0027){ref-type="ref"}      Non‐fatal MI and CV mortality                              Per SD                                                     1.59 (1.25‐2.02)                                          Age, sex, BMI, LDL/HDL ratio, smoking, diabetes, hypertension, and number of diseased vessels.
  Wiklund et al,[28](#clc23159-bib-0028){ref-type="ref"}       All‐cause mortality                                        Highest level vs lowest (\>1800 ng/L vs \<1200 ng/L)       2.61 (1.53‐4.45)[e](#clc23159-note-0007){ref-type="fn"}   Blood draw, BMI, and smoking history
  2.20 (1.47‐3.42)[f](#clc23159-note-0008){ref-type="fn"}                                                                                                                                                                                      
  Kempf et al,[5](#clc23159-bib-0005){ref-type="ref"}          All‐cause mortality                                        Per log‐unit                                               2.26 (1.52‐3.37)                                          Age, male gender, ischemic etiology, NYHA functional class, LVEF, ln NT‐proBNP, ln creatinine, Hb, ln uric acid, ln GF‐15.
  Widera et al,[29](#clc23159-bib-0029){ref-type="ref"}        Death                                                      Per SD                                                     2.4 (1.9‐3.0)[g](#clc23159-note-0009){ref-type="fn"}      Unadjusted
  Richter et al,[30](#clc23159-bib-0030){ref-type="ref"}       All‐cause mortality                                        Per SD                                                     1.22 (1.03‐1.45)                                          Age, sTRAIL, NT‐proBNP, sFAS, GDF‐15, Fractalkine, GDF‐15, COPD
  Velders et al,[31](#clc23159-bib-0031){ref-type="ref"}       CVD mortality                                              Highest quartile vs lowest                                 2.27 (1.32‐4.09)                                          Age, gender, DM, Killip class, admission heart rate, admission SBP, history of congestive heart failure, peripheral arterial disease, cystatin C, previous MI, previous PCI, previous CABG, randomized treatment arm (ticagrelor/clopidogrel), extent of CAD, NT‐proBNP, cTnT‐hs
  Per SD                                                       1.42 (1.25‐1.61)                                                                                                                                                                
  Dallmeier et al,[32](#clc23159-bib-0032){ref-type="ref"}     All‐cause mortality                                        Highest level vs lowest (\>1800 ng/L vs \<1200 ng/L)       1.73 (1.02‐2.94)                                          Age, sex, BMI, smoking, diabetes, HTN, TC, HDL‐C, use of statins, cystatin C, NT‐proBNP, hs‐CRP, and hs‐cTnT
  Wallentin et al,[33](#clc23159-bib-0033){ref-type="ref"}     All‐cause mortality                                        Highest quartile vs lowest                                 2.10 (1.63‐2.73)                                          Randomized treatment, previous warfarin/vitamin K antagonist treatment, geographic region, age, sex, BMI, smoking status, sBP, heart rate, atrial fibrillation type, DM, history of symptomatic congestive HF, previous stroke/systemic embolism/transient ischemic attack, HTN, previous MI, previous peripheral artery disease/coronary artery bypass graft/percutaneous coronary intervention, cTnI, NT‐proBNP, cystatin‐C.
  Eggers et al,[34](#clc23159-bib-0034){ref-type="ref"}        All‐cause mortality                                        Per SD                                                     2.0 (1.6‐2.5)                                             Age, hypertension, diabetes, previous AMI, previous heart failure, heart rate and sBP on admission, ST‐segment depression on admission, and peak cTnI N0.07 μg/L (within 24 hours), GRACE risk score.
  Dieplinger et al,[35](#clc23159-bib-0035){ref-type="ref"}    All‐cause mortality                                        Highest level vs lowest (\>3470 ng/L vs \< ng/L)           4.83 (3.05‐7.64)                                          Unadjusted
  Per SD                                                       2.06 (1.72‐2.46)                                                                                                                                                                
  Tzikas et al,[36](#clc23159-bib-0036){ref-type="ref"}        Death/MI                                                   Per SD                                                     1.57 (1.13‐2.19)                                          GRACE score variables: heart rate, (log) creatinine, ST changes in ECG, age, systolic blood, pressure and Killip class.
  Skau et al,[37](#clc23159-bib-0037){ref-type="ref"}          All‐cause mortality                                        Per log‐unit                                               2.57(2.31‐2.85)                                           Unadjusted

ACE, angiotensin converting enzyme; AMI, acute myocardial infarction; BMI, body mass index; BNP, pro‐brain natriuretic peptide; CKD, chronic kidney disease; CI, confidence interval; CRP, C‐reactive protein; cTnI, cardiac troponin I; CVD, cardiovascular disease; DM, diabetes mellitus; ECG, electrocardiography; eGFR, estimated glomerular filtration rate; GDF‐15, growth differentiation factor‐15; HDL, high‐density lipoprotein; HF, heart failure; HR, hazard ratio; hsCRP, high sensitivity C‐reactive protein; HTN, hypertension; LDL, low‐density lipoprotein; LVEF, left ventricular ejection fraction; MACE, major adverse cardiac events; MI, myocardial infarction; NYHA, New York Heart Association; NT‐proBNP, N‐terminal pro‐brain natriuretic peptide; NSTEMI, non‐segment elevation myocardial infarction; STEMI, segment elevation myocardial infarction; SBP, systolic blood pressure.

MACE: death, reinfarction, and new congestive heart failure within 6 months after the index event.

Stable angina group.

ACS group.

Based on 451 patients with diabetic nephropathy.

Male cohort.

Twin cohort.

Derivation cohort (n = 754).

3.3. GDF‐15 and the risk of cardiovascular mortality {#clc23159-sec-0015}
----------------------------------------------------

Eight studies reported cardiovascular mortality as outcomes. Four studies handling the data as a categorical variable demonstrated that the pooled HR for highest GDF‐15 category vs lowest was 2.39 (95% CI, 1.36‐3.41) (Figure [2](#clc23159-fig-0002){ref-type="fig"}A). Moreover, when regarded GDF‐15 level as a continuous variable, the pooled HR for cardiovascular mortality from six studies was 2.11 (95% CI, 1.57‐2.66) per log‐unit ng/L increment using a random effect model. (Figure [2](#clc23159-fig-0002){ref-type="fig"}B).

![A, Forest plot showing the association between growth differentiation factor‐15 (GDF‐15) levels and cardiovascular mortality (categorical variable). Solid squares indicate HR in each study, and the size of the square is proportional to the precision of HR. The 95% CI are denoted by lines and empty diamonds represent pooled HR. B, Forest plot showing the association between GDF‐15 levels and cardiovascular mortality (continuous variable). Solid squares indicate HR in each study, and the size of the square is proportional to the precision of HR. The 95% CI are denoted by lines and empty diamonds represent pooled HR. CI, confidence interval; HR, hazard ratio. C, Forest plot showing the association between GDF‐15 levels and all‐cause mortality (categorical variable). Solid squares indicate HR in each study, and the size of the square is proportional to the precision of HR. The 95% CI are denoted by lines and empty diamonds represent pooled HR. CI, confidence interval; HR, hazard ratio. D, Forest plot showing the association between GDF‐15 levels and all‐cause mortality (continuous variable). Solid squares indicate HR in each study, and the size of the square is proportional to the precision of HR. The 95% CI are denoted by lines and empty diamonds represent pooled HR. E, Forest plot shows the association between GDF‐15 levels and complex adverse outcome (categorical variable). Solid squares indicate HR in each study, and the size of the square is proportional to the precision of HR. The 95% CI are denoted by lines and empty diamonds represent pooled HR. F, Forest plot showing the association between GDF‐15 levels and complex adverse outcome (continuous variable). Solid squares indicate HR in each study, and the size of the square is proportional to the precision of HR. The 95% CI are denoted by lines and empty diamonds represent pooled HR. ACS, acute coronary syndrome; AMI, acute myocardial infarction; CI, confidence interval; HR, hazard ratio](CLC-42-513-g002){#clc23159-fig-0002}

3.4. GDF‐15 and the risk of all‐cause mortality {#clc23159-sec-0016}
-----------------------------------------------

Figure [2](#clc23159-fig-0002){ref-type="fig"}C showed the pooled HR for all‐cause mortality comparing the highest GDF‐15 category with lowest of GDF‐15 level (HR, 2.54; 95% CI, 2.07‐3.01). When GDF‐15 concentration increased one log‐unit ng/L, 2.7‐fold of the risk of all‐cause mortality correspondingly varied (HR, 2.70; 95% CI, 2.29‐3.12 (Figure [2](#clc23159-fig-0002){ref-type="fig"}D).

3.5. GDF‐15 and the risk of complex adverse outcome {#clc23159-sec-0017}
---------------------------------------------------

We observed that GDF‐15 concentration was associated with an increased risk of complex adverse outcome (HR, 1.80; 95% CI, 1.38‐2.23), when pooling data from six studies reporting the estimates as categorical variables. (Figure [2](#clc23159-fig-0002){ref-type="fig"}E) Every log‐unit ng/L increase in GDF‐15 concentration was associated with a 95% increase in the risk of complex adverse outcome from pooling the nine studies reporting estimates risk as continuous variables (HR, 1.96; 95% CI, 1.64‐2.29). (Figure [2](#clc23159-fig-0002){ref-type="fig"}F).

3.6. Heterogeneity measurement {#clc23159-sec-0018}
------------------------------

As the heterogeneity inspection tools, meta‐regression, analysis and sensitivity analysis were carried out aimed at exploring the potential sources of heterogeneity on all‐cause mortality regarding GDF‐15 as a categorical variable or continuous variable in our study. The detailed results were displayed in the Figure [3](#clc23159-fig-0003){ref-type="fig"}A, B. Meta‐regression analysis was executed to exploit the heterogeneity stratified by such feasible causes, sample size, baseline population duration of follow‐up, assay method, and adjustment. In evidence, the aforementioned four factors were unable to strike significant heterogeneity, but whether to adjust the confounding variables may be one of the sources of heterogeneity. We conducted a sensitivity analysis based on all‐cause mortality. In the sensitivity analyses, the results suggested that the pooled HRs or 95% CI did not reflect significant difference when omitting one of the studies from the analysis. (Figure [S1](#clc23159-supitem-0001){ref-type="supplementary-material"} and [S2](#clc23159-supitem-0002){ref-type="supplementary-material"}, Supporting Information).

![A, Pooled HR and 95% CI by subgroups (sample size, baseline population, follow‐up, and assay method) of the association between growth differentiation factor‐15 (GDF‐15) levels and all‐cause mortality (categorical variable). Black dots represent HRs and bars indicate 95% CIs. B, Pooled HR and 95% CI by subgroups (sample size, baseline population, follow‐up, assay method) of the association between GDF‐15 levels and all‐cause mortality (continuous variable). Black dots represent HRs and bars indicate 95% CIs. CI, confidence interval; HR, hazard ratio; CHD, coronary heart disease; ELISA, enzyme‐linked immunosorbent assay; RIA, radioimmunoassay](CLC-42-513-g003){#clc23159-fig-0003}

3.7. Publication bias {#clc23159-sec-0019}
---------------------

Egger test showed that no publication bias was observed (coefficient 1.772, *P* = 0.201, 95% CI: −1.15‐4.66) when considered as categorical variable. The similar results also identified the relationship as the continuous variable (coefficient 1.214, *P* = 0.121, 95% CI, −0.36‐2.78). (Figure [S3](#clc23159-supitem-0003){ref-type="supplementary-material"} and [S4](#clc23159-supitem-0004){ref-type="supplementary-material"}).

4. DISCUSSION {#clc23159-sec-0020}
=============

CVD, one of the major causes of death, has drawn comprehensive attention worldwide. Serum biomarkers play a crucial role in diagnosing CVDs, moreover, providing the predictive value on adverse outcomes. Apart from traditional cardiac markers, some newly discovered serum biomarkers have been found from large amounts of research. The role of GDF‐15 as a potential risk predictor in CVDs has been investigated popularly in recent years. To the best of our knowledge, it is probably the first attempt to analyze the data from the relative literature to evaluate the association on the risk of CVDs or all‐cause mortality.

Two studies were conducted on meta‐analysis of the relationship between GDF‐15 and the different prognosis of acute coronary syndromes and heart failure separately. One of them, GDF‐15 is classified as a categorical variable for statistical analysis,[38](#clc23159-bib-0038){ref-type="ref"} and the other is as a continuous variable.[39](#clc23159-bib-0039){ref-type="ref"} In our meta‐analysis, 31 studies were included for the further integration analysis comprehensively. It was calculated that GDF‐15 was significantly increased when adverse cardiovascular events occur (cardiovascular mortality, all‐cause mortality, and complex adverse outcome). Meanwhile, GDF‐15 was classified into categorical and continuous data for analysis, respectively. Thus, we can more clearly and intuitively infer the relationship between GDF‐15 and the different outcome of CVD or all‐cause mortality. Our meta‐analyses summarize the results of different cohort studies and evaluate the association between GDF‐15 levels and the risk of CVDs or all‐cause mortality. It is indicated that higher GDF‐15 levels have an adverse relationship on the risk of CVDs or all‐cause mortality. In view of our results, compared with the lowest GDF‐15 levels, those with the highest levels have a 139% increment in the risk of CVD mortality, 154% increment in the risk of all‐cause mortality, and 80% increment in the risk of composite of death or cardiac events. When GDF‐15 level was calculated as a continuous variable, there is a 111% increment in the risk of CVD mortality per log‐unit increment, 170% increment in the risk of all‐cause mortality per log‐unit increment and 96% increment in the risk of composite of death or cardiac events. So, qualitatively and quantitatively assessment for the association between GDF‐15 levels and adverse outcomes has been performed respectively to verify the hypothesis.

Plenty of clinical researches had demonstrated that GDF‐15 is independently related to a variety of CVDs. Moreover, growth differentiation factor 15 provided more prognostic information in assessing the prognosis for the risk of adverse cardiac events or all‐cause mortality. The majority of the included literature in this analysis had verified conclusions drawn from a large number GDF‐15 prospective clinical trials, indicating that GDF‐15 may play a protective role in the pathophysiological processes.

In this meta‐analysis, we have fully integrated the studies on the basis of different research groups, including general population, cardiac disease patients, and various of diseases cases. Numerous studies have demonstrated that GDF‐15 engaged in predicting the prognosis of the diseases of different baseline populations. HF, as the end‐stage of a variety of heart disease, earlier diagnosis appears to be particularly crucial. Studies of research population of HF has showed that the concentration of GDF‐15 was markedly elevated, moreover, providing prognostic information with clinical value on all‐cause mortality.[5](#clc23159-bib-0005){ref-type="ref"} It was proved by experiment that GDF‐15 plays a protective role by inhibiting apoptosis, hypertrophy, and adverse remodeling in the injured heart. GDF‐15 also participated in the development of cardiac remodeling in HF with a function of counterworking hypertrophy and apoptosis through PI3K‐Akt, ERK1/2, and SMAD2/3 signaling pathways.[2](#clc23159-bib-0002){ref-type="ref"} A study of a large sample of AF has identified that GDF‐15 is an indicator for the prognosis of major bleeding and death.[33](#clc23159-bib-0033){ref-type="ref"} Owing to the incidence trend of ischemic heart disease, the application of GDF‐15 on early diagnosis and prognosis of disease is widely studied. In an animal model, it was confirmed that GDF‐15 played a cardioprotective role. After the occurrence of ischemia‐reperfusion (I/R), the expression of GDF‐15 was sharply enhanced in the cardiomyocytes as an endogenous protective cytokine against I/R‐induced cardiomyocyte apoptosis, possibly through PI3K‐Akt‐dependent signaling pathways. In addition, it seemed to be mediated by the approach of induction of nitric oxide (NO) synthase‐2, production of NO and peroxynitrite formation. Meanwhile, some relevant pro‐inflammatory cytokines (interferon‐γ and interleukin‐1β) involved in the induction of GDF‐15 through NO‐dependent pathways.[3](#clc23159-bib-0003){ref-type="ref"} Besides, GDF‐15, has provided more valuable information for risk stratification and prognosis in CVDs.[11](#clc23159-bib-0011){ref-type="ref"} An epidemiological research demonstrates that GDF‐15 levels are associated with carotid artery intima‐media thickness, plaque burden, and endothelial dysfunction in elderly individuals, which may provide insight into disparate mechanism of GDF‐15 pathophysiology.[40](#clc23159-bib-0040){ref-type="ref"} Some studies included in our meta‐analysis demonstrate that GDF‐15 has performed well both in identifying stable and unstable CAD and in evaluating the prognosis, and likewise, independent of traditional clinical risk biomarkers, such as troponin T, NT‐proBNP, and hs‐CRP.[6](#clc23159-bib-0006){ref-type="ref"}, [13](#clc23159-bib-0013){ref-type="ref"}, [15](#clc23159-bib-0015){ref-type="ref"} To find the potential heterogeneity, we did meta‐regression analysis and sensitivity analysis to identify conceivable sources of the discrepancy from the studies that reported all‐cause mortality as endpoints. Several probable aspects were filtered for the subgroup analyses. Paradoxically, the results of meta‐regression analysis and sensitive analysis was failed to elucidate that where the heterogeneity stems from genuinely. It was inexplicit that which was the initiator of the difference. Furthermore, the results of the sensitivity analysis also indicated that the elimination of any study did not make a significant alteration in the pooled HR.

In conclusion, it can be noted that the present study has stated the association between GDF‐15 and adverse prognosis of CVDs and all‐cause mortality. A large number of research need to be done until GDF‐15 could contribute to clinical and bring more valuable information for clinician.

5. LIMITATION {#clc23159-sec-0021}
=============

We delimit the studies published in the English language as one of the eligible criteria, which may be a limiting factor. First based on prospective study data, the result of our meta‐analysis is subject to potential bias. Although potential confounders, such as age, sex, and body mass index have been adjusted in most studies, residual confounding cannot be precluded. Second, some studies of small sample size resulting in extremely strong associations may have an impact on pooled estimates. Third, the characteristics of baseline participants differ across included studies which cause the initial production of heterogeneity. Fourth, on account of disparate adjusted variables of each study it is arduous to unify the diverse adjustments for all studies. Fifth, a dose‐effect relationship between the GDF‐15 level and all‐cause mortality or adverse cardiac events is failed to be conducted owing to the lack of indispensable data. In addition, the indefinite cutoff point of GDF‐15 and the various assay methods may influence the results. The relative small sample sizes of studies attenuate the strength of this meta‐analysis. Furthermore, larger numbers of studies are expected to strengthen our results, which may provide more vital information on the diagnosis and prognosis for CVDs.

6. CONCLUSION {#clc23159-sec-0022}
=============

Elevated GDF‐15 may increase risk of all‐cause mortality and adverse cardiovascular events. Further and more detailed clinical investigations are needed to conduct to identify whether measurement of GDF‐15 can be applied to clinical patients for an effective earlier diagnosis, risk stratification, and prognosis assessment.
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**FIGURE S1** HR and 95% CI by omitting each study from the eligible studies of the association between GDF‐15 levels and all‐cause mortality (categorical variable). Empty dots represent HRs and bars indicate 95% CIs. CI, confidence interval; HR, hazard ratio

###### 

Click here for additional data file.
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**FIGURE S2** HR and 95% CI by omitting each study from the eligible studies of the association between GDF‐15 levels and all‐cause mortality (continuous variable). Empty dots represent HRs and bars indicate 95% CIs. CI, confidence interval; HR, hazard ratio; ACS: acute coronary syndrome; AMI: acute myocardial infarction
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**FIGURE S3** Egger\'s funnel plot (with pseudo 95% CIs) to detect any publication bias for the association between GDF‐15 level and all‐cause mortality as categorical variables. Empty dots denote effect size of each study; CI, confidence interval
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Click here for additional data file.
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**FIGURE S4** Egger\'s funnel plot (with pseudo 95% CIs) to detect any publication bias for the association between GDF‐15 level and all‐cause mortality as continuous variables. Empty dots denote effect size of each study; CI, confidence interval
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Click here for additional data file.
